Compare CVS Health Corp (CVS) vs First Citizens BancShares Inc (FCNCA) Price & Performance

CVS Health trades at $94.70, down 1.01% with strong technical support at $93-$91 levels. The company reported robust Q2 2026 earnings of $2.58 per share, beating estimates by 38%, while raising full-year guidance. Revenue growth accelerated to 7.3% year-over-year, driven by Aetna's recovery and retail strength. Analyst consensus remains overwhelmingly bullish with 84% buy ratings and a $115.90 price target representing 22% upside potential.

CVS presents compelling value with a 0.29 P/S ratio and positive earnings momentum, though net margins remain thin at 1.18%. Key risks include 2027 PBM pressure and healthcare regulatory changes. The stock's current technical weakness near support levels offers potential entry point for long-term investors seeking exposure to integrated healthcare services.

First Citizens BancShares (FCNCA) trades at $2,271.31, up 1.7% on the day, with a bullish technical signal from moving averages and recent earnings beats. The stock shows strong fundamentals with a P/E of 12.08 and net income margin of 25.23%, supported by consistent revenue around $9.3B. Recent news highlights expansion in commercial lending and strategic leadership appointments, reinforcing growth initiatives.

Outlook remains positive due to earnings momentum and dividend stability, but risks include elevated uninsured deposits and net interest margin pressure. Analyst consensus is cautious with 82% hold ratings, suggesting limited near-term upside despite a $2,310 price target. Investors should weigh solid profitability against sector headwinds and valuation constraints.